Tenofovir
Aims to educate members and provide a forum to brainstorm ideas about the way to most effectively represent clients negatively impacted by tenofovir. The group provides member benefits such as access to pleadings, discovery, legal research, listserves, education programs, a medical literature database, and opportunities to share ideas in educational meetings.
Join the Litigation GroupTenofovir
Over a 14-year period, Gilead Sciences, Inc. ("Gilead") profited from exposing its patients to TDF-based medications by actively concealing and failing to bring to market safer, more effective TAF-based alternatives. Had Gilead acted reasonably under the circumstances in which it developed tenofovir as an antiretroviral treatment for HIV-1, it would have abandoned TDF in favor of TAF, thus reducing the risk of foreseeable and avoidable injuries like chronic kidney disease, renal failure, and bone mineral density disorders.
The Tenofovir Litigation Group aims to educate members and provide a forum to brainstorm ideas about how to most effectively represent clients negatively impacted by tenofovir. The Group provides member benefits such as access to pleadings, discovery, legal research, list servers, education programs, a medical literature database, and opportunities to share ideas in educational meetings.
The Tenofovir Litigation Group is sponsored by Epiq.
- Meetings: The group meets at AAJ Annual and Winter conventions.
- Membership: The group is limited to AAJ Regular, Life, Sustaining, and President’s Club members only.
- Annual Dues: $300 for first member/$100 for additional members from the same firm (no firm paying more than $400).
Cochairs
Adam Gomez | Grant & Eisenhofer, PA, Wilmington, DE
Robert Jenner | Jenner Law, PC, Baltimore, MD
Litigation Group members, visit AAJ's Community Center to connect with your colleagues on the list server, search discussion archives, download documents, update your list server settings, and more. Lit Group Member Login
